The risk of developing cardiovascular diseases (CVD) is dramatically increased in patients with chronic kidney diseases (CKD). Mechanisms leading to this cardiorenal syndrome (CRS) are multifactorial, and combined analyses of both failing organs may provide routes toward developing strategies for early risk assessment, prognosis, and consequently effective therapy. In order to identify molecular mechanisms involved in the crosstalk between the diseased cardiovascular system and kidney, we analyzed tissue specific transcriptomics profiles on atherosclerosis and diabetic nephropathy together with gene sets associated with cardiovascular and chronic kidney diseases that derived from a literature mining approach. We focused on enriched molecular pathways and highlight molecular interactions found within as well as between affected pathways identified for the two organs. Analysis on the level of molecular pathways pointed out the role of PPAR signaling, coagulation, inflammation, and focal adhesion pathways in formation and progression of the CRS. The proteins apolipoprotein A1 (APOA1) and albumin (ALB) turned out to be of particular importance in the context of dyslipidemia, one of the major risk factors for the development of CVD. In summary, our analyses highlight mechanisms associated with dyslipidemia, hemodynamic regulation, and inflammation on the interface between the cardiovascular and the renal system.
Get full access to this article
View all access options for this article.
References
1.
AnavekarN.S., McMurrayJ.J.V., VelazquezE.J., SolomonS.D., KoberL., RouleauJ.-L.et al.2004. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med, 351:1285–1295.
2.
AndrikoulaM., McDowellI.F.W.2008. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab, 10:271–278.
3.
AshburnerM., BallC.A., BlakeJ.A., BotsteinD., ButlerH., CherryJ.M.et al.2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet, 25:25–29.
4.
AttmanP.O., Knight-GibsonC., TavellaM., SamuelssonO., AlaupovicP.1998. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant, 13:2833–2841.
5.
BerlT., HenrichW.2006. Kidney–heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol, 1:8–18.
6.
BongartzL.G., CramerM.J., DoevendansP.A., JolesJ.A., BraamB.2005. The severe cardiorenal syndrome: “Guyton revisited. Eur Heart J, 26:11–17.
DahlC.P., GullestadL., FevangB., HolmA.M., LandrøL., VingeL.E.et al.2008. Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure. Eur J Heart Failure, 10:352–359.
9.
FassotC., BrietM., RostagnoP., BarbryP., PerretC., LaudeD.et al.2008. Accelerated arterial stiffening and gene expression profile of the aorta in patients with coronary artery disease. J Hypertens, 26:747–757.
10.
FecheteR., HeinzelA., PercoP., MönksK., SöllnerJ., StelzerG.et al.2011. Mapping of molecular pathways, biomarkers and drug targets for diabeticnephropathy. Proteomics Clin Appl, 5:354–366.
11.
GilbertR.E., CooperM.E.1999. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?Kidney Int, 56:1627–1637.
12.
JudsonW.E., HelmerO.M.1971. Relationship of cardiorenal function to renin–aldosterone system in patients with valvular heart disease. Circulation, 44:245–253.
13.
KanehisaM., GotoS.2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res, 28:27–30.
14.
KannelW.B.2005. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids, 40:1215–1220.
KimK.J., YangW.S., KimS.B., LeeS.K., ParkJ.S.1997. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Peritoneal Dial Int, 17:157–161.
17.
KirmizisD., TsiandoulasA., PangalouM., KoutoupaE., RoziP., ProtopappaM.et al.2006. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monitor, 12:CR55–CR62.
18.
KoniariK., NikolaouM., ParaskevaidisI., ParissisJ.2010. Therapeutic options for the management of the cardiorenal syndrome. Int J Nephrol, 2011; 194910.
19.
KurataA., NishizawaH., KiharaS., MaedaN., SonodaM., OkadaT.et al.2006. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int, 70:1717–1724.
20.
LeeC.R., WatkinsM.L., PattersonJ.H., GattisW., O'ConnorC.M., GheorghiadeM.et al.2003. Vasopressin: a new target for the treatment of heart failure. Am Heart J, 146:9–18.
21.
LetavernierE., PerezJ., JoyeE., BellocqA., FouquerayB., HaymannJ.-P.et al.2005. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol, 16:2395–2402.
22.
LindnerA., CharraB., SherrardD.J., ScribnerB.H.1974. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med, 290:697–701.
23.
LynchA.I., BoerwinkleE., DavisB.R., FordC.E., EckfeldtJ.H., Leiendecker-FosterC.et al.2009. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant −455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics, 19:415–421.
24.
McCulloughP.A., VerrillT.A.2010. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med, 122:25–34.
25.
MitchellD.A., TaylorP.R., CookH.T., MossJ., BygraveA.E., WalportM.J.et al.1999. Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol, 162:5676–5679.
26.
MorangeP.E., BickelC., NicaudV., SchnabelR., RupprechtH.J., PeetzD.et al.2006. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol, 26:2793–2799.
27.
MühlbergerI., MoenksK., BernthalerA., JandrasitsC., MayerB., MayerG.et al.2010. Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome. Int J Nephrol, 2011; 809378.
28.
NathK.A.1998. The tubulointerstitium in progressive renal disease. Kidney Int, 54:992–994.
29.
PercoP., MühlbergerI., MayerG., OberbauerR., LukasA., MayerB.2010. Linking transcriptomic and proteomic data on the level of protein interaction networks. Electrophoresis, 31:1780–1789.
30.
RoncoC., HaapioM., HouseA.A., AnavekarN., BellomoR.2008. Cardiorenal syndrome. J Am College Cardiol, 52:1527–1539.
31.
RoncoC., McCulloughP.A., AnkerS.D., AnandI., AspromonteN., BagshawS.M.et al.2010. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI)Contrib Nephrol, 165:54–67.
32.
RostandS.G., KirkK.A., RutskyE.A.1986. The epidemiology of coronary artery disease in patients on maintenance hemodialysis: implications for management. Contrib Nephrol, 52:34–41.
33.
RyanK.E., McCanceD.R., PowellL., McMahonR., TrimbleE.R.2007. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis, 194:e123–e130.
34.
SarnakM.J., LeveyA.S., SchoolwerthA.C., CoreshJ., CulletonB., HammL.L.et al.2003. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 42:1050–1065.
35.
SchiffrinE.L.2005. More evidence of cardiorenal protective effects of peroxisome proliferator-activated receptor activation. Hypertension, 46:267–268.
36.
SchiffrinE.L., LipmanM.L., MannJ.F.E.2007. Chronic kidney disease: effects on the cardiovascular system. Circulation, 116:85–97.
37.
SchmidH., BoucherotA., YasudaY., HengerA., BrunnerB., EichingerF.et al.2006. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes, 55:2993–3003.
38.
SilversteinD.M.2009. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol, 24:1445–1452.
39.
SjølandJ.A., SidelmannJ.J., BrabrandM., PedersenR.S., PedersenJ.H., EsbensenK.et al.2007. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemostasis, 98:339–345.
40.
ToyodaT., KameiY., KatoH., SugitaS., TakeyaM., SuganamiT.et al.2008. Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue. Obesity, 16:1199–1207.
41.
VolgerO.L., FledderusJ.O., KistersN., FontijnR.D., MoerlandP.D., KuiperJ.et al.2007. Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis. Am J Pathol, 171:326–337.
42.
WernerC., KamaniC.H., GenschC., BöhmM., LaufsU.2007. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes, 56:2609–2615.
43.
WilliamsJ.M., ZhaoX., WangM.H., ImigJ.D., PollockD.M.2005. Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension, 46:366–371.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
